Rivaroxaban (Xarelto®): Guide de la pratique officinale

J Douxfils; S Michel; C Beauloye; M Goethals; P Hainaut; H Heidbuchel; C Hermans; B Ickx; K Jochmans; S Mottes; F Mullier; A Peeters; C Scavée; P Sinnaeve; M Sprynger; V Thijs; C Vandenbroeck; E Vandermeulen; P Verhamme; J M Dogné

Rivaroxaban (Xarelto®): Guide de la pratique officinale

Translated title of the contribution: Rivaroxaban: Xarelto® - Recommendations for pharmacists

J Douxfils, S Michel, C Beauloye, M Goethals, P Hainaut, H Heidbuchel, C Hermans, B Ickx, K Jochmans, S Mottes, F Mullier, A Peeters, C Scavée, P Sinnaeve, M Sprynger, V Thijs, C Vandenbroeck, E Vandermeulen, P Verhamme, J M Dogné

Research output: Contribution to journal › Review article › peer-review

976 Downloads (Pure)

Abstract

Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

Translated title of the contribution	Rivaroxaban: Xarelto® - Recommendations for pharmacists
Original language	French
Pages (from-to)	28-36
Number of pages	9
Journal	Journal de Pharmacie de Belgique
Issue number	1
Publication status	Published - 1 Mar 2013

Keywords

Anticoagulants
Humans
Morpholines
Pharmacists
Thiophenes
Venous Thrombosis
Vitamin K

Access to Document

Journ. Ph. Belg. 2013 - Guide pratique du rivaroxabanFinal published version, 900 KB

Cite this

Douxfils, J., Michel, S., Beauloye, C., Goethals, M., Hainaut, P., Heidbuchel, H., Hermans, C., Ickx, B., Jochmans, K., Mottes, S., Mullier, F., Peeters, A., Scavée, C., Sinnaeve, P., Sprynger, M., Thijs, V., Vandenbroeck, C., Vandermeulen, E., Verhamme, P., & Dogné, J. M. (2013). Rivaroxaban (Xarelto®): Guide de la pratique officinale. Journal de Pharmacie de Belgique, (1), 28-36.

@article{b0392481c05a4b8197c9baf853e7f3bb,

title = "Rivaroxaban (Xarelto{\textregistered}): Guide de la pratique officinale",

abstract = "Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto{\textregistered} in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.",

keywords = "Anticoagulants, Humans, Morpholines, Pharmacists, Thiophenes, Venous Thrombosis, Vitamin K",

author = "J Douxfils and S Michel and C Beauloye and M Goethals and P Hainaut and H Heidbuchel and C Hermans and B Ickx and K Jochmans and S Mottes and F Mullier and A Peeters and C Scav{\'e}e and P Sinnaeve and M Sprynger and V Thijs and C Vandenbroeck and E Vandermeulen and P Verhamme and Dogn{\'e}, {J M}",

year = "2013",

month = mar,

day = "1",

language = "Fran{\c c}ais",

pages = "28--36",

journal = "Journal de Pharmacie de Belgique",

issn = "0047-2166",

publisher = "APB Algemene Pharmaceutische Bond",

number = "1",

}

Douxfils, J, Michel, S, Beauloye, C, Goethals, M, Hainaut, P, Heidbuchel, H, Hermans, C, Ickx, B, Jochmans, K, Mottes, S, Mullier, F, Peeters, A, Scavée, C, Sinnaeve, P, Sprynger, M, Thijs, V, Vandenbroeck, C, Vandermeulen, E, Verhamme, P & Dogné, JM 2013, 'Rivaroxaban (Xarelto®): Guide de la pratique officinale', Journal de Pharmacie de Belgique, no. 1, pp. 28-36.

TY - JOUR

T1 - Rivaroxaban (Xarelto®)

T2 - Guide de la pratique officinale

AU - Douxfils, J

AU - Michel, S

AU - Beauloye, C

AU - Goethals, M

AU - Hainaut, P

AU - Heidbuchel, H

AU - Hermans, C

AU - Ickx, B

AU - Jochmans, K

AU - Mottes, S

AU - Mullier, F

AU - Peeters, A

AU - Scavée, C

AU - Sinnaeve, P

AU - Sprynger, M

AU - Thijs, V

AU - Vandenbroeck, C

AU - Vandermeulen, E

AU - Verhamme, P

AU - Dogné, J M

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

AB - Rivaroxaban is one of the new oral anticoagulants (NOACs) (recommended as reference treatments when a long-term anticoagulation is needed). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto® in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.

KW - Anticoagulants

KW - Humans

KW - Morpholines

KW - Pharmacists

KW - Thiophenes

KW - Venous Thrombosis

KW - Vitamin K

UR - http://www.scopus.com/inward/record.url?scp=84876403985&partnerID=8YFLogxK

M3 - Article de revue

C2 - 23638610

SN - 0047-2166

SP - 28

EP - 36

JO - Journal de Pharmacie de Belgique

JF - Journal de Pharmacie de Belgique

IS - 1

ER -

Rivaroxaban (Xarelto®): Guide de la pratique officinale

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.

Cite this

Rivaroxaban (Xarelto®): Guide de la pratique officinale

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Student theses

Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.

Cite this